Fifth Third Bancorp Grows Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Fifth Third Bancorp grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 22.7% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 487 shares of the biotechnology company’s stock after purchasing an additional 90 shares during the period. Fifth Third Bancorp’s holdings in United Therapeutics were worth $150,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. raised its holdings in United Therapeutics by 18.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 65,405 shares of the biotechnology company’s stock worth $20,162,000 after acquiring an additional 10,290 shares during the last quarter. Nepsis Inc. raised its holdings in United Therapeutics by 6.7% in the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company’s stock worth $18,057,000 after acquiring an additional 3,653 shares during the last quarter. SG Americas Securities LLC raised its holdings in United Therapeutics by 210.9% in the 1st quarter. SG Americas Securities LLC now owns 10,085 shares of the biotechnology company’s stock worth $3,109,000 after acquiring an additional 6,841 shares during the last quarter. Signet Financial Management LLC raised its holdings in United Therapeutics by 0.7% in the 1st quarter. Signet Financial Management LLC now owns 10,895 shares of the biotechnology company’s stock worth $3,359,000 after acquiring an additional 79 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in United Therapeutics by 20.3% in the 1st quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 77 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of UTHR stock opened at $291.72 on Friday. The company has a market cap of $13.16 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 6.39 and a beta of 0.57. The firm has a fifty day moving average price of $300.79 and a 200-day moving average price of $328.53. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. United Therapeutics’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.17 EPS. Equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research note on Thursday, May 1st. Morgan Stanley boosted their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research note on Thursday, May 1st. Wall Street Zen lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Wells Fargo & Company reiterated an “equal weight” rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Finally, Bank of America decreased their target price on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research note on Wednesday, June 11th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $393.08.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,297,208.76. This represents a 23.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 12,000 shares of the company’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the sale, the chief financial officer now owns 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $23,907,950 in the last 90 days. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.